Novavax Stock News

Novavax Inc. (NASDAQ: NVAX ) shares were moving this week after the head of the Vaccines Task Force for the European Medicines Agency said Tuesday the company''s COVID-19 vaccine could soon receive authorization in Europe. Novavax shares were down 1.05% at $179.83 Thursday afternoon. See Also: Novavax Stock Climbs Back Into Pattern On Vaccine News Novavax Daily Chart Analysis Shares are pushing higher in what traders call a pennant pattern, nearing an area of resistance. The stock has seen months of Full story available on Benzinga.com

United Maritime Capital LLC decreased its holdings in Novavax, Inc. (NASDAQ:NVAX) by 4.2% in the 3rd quarter, Holdings Channel reports. The institutional investor owned 2,255 shares of the biopharmaceutical companys stock after selling 100 shares during the period. United Maritime Capital LLCs holdings in Novavax were worth $467,000 at the end of the most recent []

Novavax, Inc. (NASDAQ:NVAX) shares gapped up before the market opened on Thursday . The stock had previously closed at $181.75, but opened at $188.74. Novavax shares last traded at $184.06, with a volume of 26,146 shares traded. Several research analysts recently weighed in on NVAX shares. Chardan Capital restated a neutral rating on shares of []

The European Medicines Agency (EMA) said on Thursday that there is a possibility it will grant approval of the Novavax COVID-19 vaccine Nuvaxovid before the end of the year. "When authorized, th

Wall Street analysts predict that Novavax, Inc. (NASDAQ:NVAX) will post earnings of $0.36 per share for the current fiscal quarter, Zacks reports. Four analysts have provided estimates for Novavaxs earnings. The lowest EPS estimate is ($4.95) and the highest is $7.89. Novavax posted earnings of ($2.70) per share during the same quarter last year, which []

NEW ORLEANS, Dec. 08, 2021 (GLOBE NEWSWIRE) -- ClaimsFiler, a FREE shareholder information service, reminds investors of pending deadlines in the following securities class action lawsuits:

Related Stocks: AMGN , NVAX , ITCI , SRPT , BGNE , GH , ALKS , AZN , CRBU , CRL , RLYB , BHVN , ALLK , BPMC , BBIO , IOVA , DCPH , REPL ,

(PR-inside.com) BOSTON, MA / ACCESSWIRE / December 8, 2021 / The Thornton Law Firm alerts investors that a class action lawsuit has been filed on behalf of investors of Novavax, Inc. (NASDAQ:NVAX). The case is currently in the lead plaintiff stage. Investors who purchased NVAX securities between March 2, 2021 and October 19, 2021 may contact the Thornton Law Firm''s investor protection team by visiting www.tenlaw.com/cases/Novavax for more information. Investors may also email [email protected] or call 617-531-3917. FOR MORE INFORMATION: www.tenlaw.com/cases/Novavax The case alleges that Novavax and its senior executives made misleading statements to investors and failed to disclose that: (i) Novavax overstated ..

Pomerantz LLP announces that a class action lawsuit has been filed against Novavax, Inc. and certain of its officers. The class action, filed in the United States District Court for the District of Maryland, Southern Division, and docketed under 21-cv-02910, is on behalf of []

(PR-inside.com) NEW YORK, NY / ACCESSWIRE / December 8, 2021 / The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Novavax, Inc. (NASDAQ:NVAX) alleging that the Company violated federal securities laws. Class Period: March 2, 2021 to October 19, 2021Lead Plaintiff Deadline: January 11, 2022No obligation or cost to you. Learn more about your recoverable losses in NVAX:https://www.kleinstocklaw.com/pslra-1/novavax-inc-loss-submission-form-2?id=21987&from=5 Novavax, Inc. NEWS - NVAX NEWS CLASS ACTION CASE DETAILS: The filed complaint alleges that Novavax, Inc. made materially false and/or misleading statements and/or failed to disclose that: (i) Novavax overstated its manufacturing capabilities and downplayed manufacturing issues ..

Dublin, Dec. 08, 2021 (GLOBE NEWSWIRE) -- The "Vaccine Adjuvants Market - Growth, Trends, COVID-19 Impact, and Forecasts (2021-2026)" report has been added to ResearchAndMarkets.com''s offering.

CEDARHURST, N.Y., Dec. 07, 2021 (GLOBE NEWSWIRE) -- The securities litigation law firm of Kuznicki Law PLLC issues this alert to shareholders of the following publicly traded companies.

South Korea daily cases top 7,000 for first time; stealth version of Omicron cannot be detected by routine tests; Boris Johnson staff filmed joking about No 10 party WHO Europe: jab young children to cut Covid risk at Christmas Moderna or Novavax after AstraZeneca jab confers high immunity: study Up to 6m eligible Britons may not have had a jab. Who are they? Podcast: How fast is the Omicron variant spreading? See all our coronavirus coverage South Koreas government is scrambling to bolster the countrys health system amid a surge in Covid cases that has seen the daily tally rise past 7,000 for the time since the pandemic began almost two years ago. The Korea Disease Control and Prevention Agency (KDCA) reported 7,175 new coronavirus cases and 63 deaths for Tuesday, and hospitals are treating a record 840 critical and serious cases. Continue reading